PZRX News

The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its $281 million IPO raised more than the other three small health care deals combined.  ...read more

PhaseRx, a preclinical biotech developing treatments for inherited enzyme deficiencies in the liver, raised $19 million by offering 3.7 million shares at $5, the low end of the range of $5 to $7. PhaseRx plans to list on the Nasdaq under the symbol PZRX. Laidlaw & Company (UK) and Roth Capital acted as lead managers on the deal....read more

There are four companies set to debut in the week ahead, but only one company with substantial revenue and profit - small-cap Argentinian bank Grupo Supervielle (SUPV). Three additional deals launched and are set to price in May including the second-largest food distributor US Foods (USFD), set to raise $1 billion. If all deals on the calendar...read more

Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying. ...read more